# Millie Ray

> Millie Ray is a Series B investor at The Column Group backing Health Care and Therapeutics. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [The Column Group](https://shizune.co/investors/profile/the-column-group)
- Total investments: 5
- Last investment: Nov 2022
- Lead investor: 40%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/mridulakray/

Millie Ray is a Series B investor at The Column Group focused on Health Care and Therapeutics. Dr. Ray joined The Column Group in 2017. Previously, Dr. Ray was an Associate of Business Development at Foghorn Therapeutics, which she helped launch with Flagship Pioneering. Dr. Ray helped develop and execute the scientific, business and operating plans for Foghorn Therapeutics. Dr. Ray helped establish the first onsite next-generationsequencers for Ebola viral surveillance with Dr. Pardis Sabeti’s lab at Harvard University and the Broad Institute. Previously, Dr. Ray completed her PhD at Harvard University with Dr. Robert Kingston, studying the effects of long non-coding RNAs on epigenetic regulation. Dr. Ray holds undergraduate degrees in Biology and Mathematics from the Massachusetts Institute of Technology, where she also performed embryonic stem cell research in the lab of Dr. Rudolf Jaenisch.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 40% |
| Therapeutics | 2 | 40% |
| Biotechnology | 2 | 40% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 2 | 40% |
| Series A | 1 | 20% |
| Series C | 1 | 20% |
| Venture - Series Unknown | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Casma Therapeutics | Casma Therapeutics is a developer of a natural cellular process of autophagy to open new target areas for drug discovery and development. The company focuses on autophagy system to improve the cellular process of clearing out unwanted proteins, organelles and invading pathogens as well as tries to arrest or reverse the progression of lysosomalstorage disorders, muscle disorders, inflammatory disorders and neurodegeneration, enabling physicians to address unmet medical needs. | $46M | Series C | Nov 15, 2022 |  |
| Hexagon Bio | Hexagon Bio is a data-driven biotech developing targeted small molecule therapeutics. Our proprietary platform combines data science and synthetic biology to discover and engineer drugs from DNA sequences. We are mining fungal genomes for inspiration for the next generation of targeted therapies for diseases with unmet needs. | $77.3M | Series B | Oct 11, 2022 |  |
| Hexagon Bio | Hexagon Bio is a data-driven biotech developing targeted small molecule therapeutics. Our proprietary platform combines data science and synthetic biology to discover and engineer drugs from DNA sequences. We are mining fungal genomes for inspiration for the next generation of targeted therapies for diseases with unmet needs. | $61M | Venture - Series Unknown | Sep 22, 2021 |  |
| Hexagon Bio | Hexagon Bio is a data-driven biotech developing targeted small molecule therapeutics. Our proprietary platform combines data science and synthetic biology to discover and engineer drugs from DNA sequences. We are mining fungal genomes for inspiration for the next generation of targeted therapies for diseases with unmet needs. | $47M | Series A | Sep 15, 2020 |  |
| Casma Therapeutics | Casma Therapeutics is a developer of a natural cellular process of autophagy to open new target areas for drug discovery and development. The company focuses on autophagy system to improve the cellular process of clearing out unwanted proteins, organelles and invading pathogens as well as tries to arrest or reverse the progression of lysosomalstorage disorders, muscle disorders, inflammatory disorders and neurodegeneration, enabling physicians to address unmet medical needs. | $50M | Series B | Sep 10, 2020 |  |

5 of 5 investments shown.

## Co-investors
- [8VC](https://shizune.co/investors/profile/8vc) — VC Fund, 3 deals together
- [Third Rock Ventures](https://shizune.co/investors/profile/third-rock-ventures) — VC Fund, 3 deals together
- [Two Sigma Ventures](https://shizune.co/investors/profile/two-sigma-ventures) — VC Fund, 3 deals together
- [Nextech Invest](https://shizune.co/investors/profile/nextech-invest) — VC Fund, 2 deals together
- [Amgen Ventures](https://shizune.co/investors/profile/amgen-ventures) — VC Fund, 1 deal together
- [Astellas Venture Management](https://shizune.co/investors/profile/astellas-venture-management) — VC Fund, 1 deal together

## About The Column Group

VC Fund · San Francisco, United States

The Column Group is a venture capital firm dedicated to creating the next generation of biotechnology companies. They manage over $4 billion in assets and focus on building companies with groundbreaking scientific platforms that have the potential to deliver significant new therapies for unmet medical needs. TCG takes a long-term approach, aimingto develop companies capable of generating multiple product opportunities rather than focusing on quick exits.

5 contacts available at The Column Group.

| Name | Title | Profile |
| --- | --- | --- |
| David Goeddel | Managing Partner | https://shizune.co/investors/profile/david-v-goeddel |
| Jeff Goater | Venture Partner | https://shizune.co/investors/profile/dinah-sah-2 |
| Joseph Goldstein | Science Partner | https://shizune.co/investors/profile/joseph-l-goldstein |
| Millie Ray | Partner | https://shizune.co/investors/profile/millie-ray |
| Peter Svennilson | Managing Partner and Founder | https://shizune.co/investors/profile/peter-svennilson |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Millie Ray invest in?

Millie Ray invests primarily in Health Care, Therapeutics and Biotechnology startups, most often at Series B and Series A stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Millie Ray last invest?

The most recent investment recorded for Millie Ray closed in Nov 2022. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co